These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 6250760)

  • 1. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
    Ohlsson A; Lindgren JE; Wahlen A; Agurell S; Hollister LE; Gillespie HK
    Clin Pharmacol Ther; 1980 Sep; 28(3):409-16. PubMed ID: 6250760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis.
    Lindgren JE; Ohlsson A; Agurell S; Hollister L; Gillespie H
    Psychopharmacology (Berl); 1981; 74(3):208-12. PubMed ID: 6267648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication?
    Hollister LE; Gillespie HK; Ohlsson A; Lindgren JE; Wahlen A; Agurell S
    J Clin Pharmacol; 1981; 21(S1):171S-177S. PubMed ID: 6271822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.
    Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H
    Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes.
    Brenneisen R; Meyer P; Chtioui H; Saugy M; Kamber M
    Anal Bioanal Chem; 2010 Apr; 396(7):2493-502. PubMed ID: 20112012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.
    Wall ME; Sadler BM; Brine D; Taylor H; Perez-Reyes M
    Clin Pharmacol Ther; 1983 Sep; 34(3):352-63. PubMed ID: 6309462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of oral delta-9 tetrahydrocannabinol (THC) in children receiving cannabis extracts for epilepsy.
    Wang GS; Bourne DWA; Klawitter J; Sempio C; Chapman K; Knupp K; Wempe MF; Borgelt L; Christians U; Heard K; Bajaj L
    Clin Toxicol (Phila); 2020 Feb; 58(2):124-128. PubMed ID: 31111749
    [No Abstract]   [Full Text] [Related]  

  • 8. Disposition of smoked cannabis with high Δ(9)-tetrahydrocannabinol content: a kinetic model.
    Hunault CC; van Eijkeren JC; Mensinga TT; de Vries I; Leenders ME; Meulenbelt J
    Toxicol Appl Pharmacol; 2010 Aug; 246(3):148-53. PubMed ID: 20450927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.
    Fabritius M; Chtioui H; Battistella G; Annoni JM; Dao K; Favrat B; Fornari E; Lauer E; Maeder P; Giroud C
    Anal Bioanal Chem; 2013 Dec; 405(30):9791-803. PubMed ID: 24202191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Δ(9) -tetrahydrocannabinol detection using DrugWipe5S(®) screening and oral fluid quantification after Quantisal™ collection for roadside drug detection via a controlled study with chronic cannabis users.
    Wille SM; Di Fazio V; Toennes SW; van Wel JH; Ramaekers JG; Samyn N
    Drug Test Anal; 2015 Mar; 7(3):178-86. PubMed ID: 24753449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey.
    Perlin E; Smith CG; Nichols AI; Almirez R; Flora KP; Cradock JC; Peck CC
    J Pharm Sci; 1985 Feb; 74(2):171-4. PubMed ID: 2985774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.
    Vandrey R; Herrmann ES; Mitchell JM; Bigelow GE; Flegel R; LoDico C; Cone EJ
    J Anal Toxicol; 2017 Mar; 41(2):83-99. PubMed ID: 28158482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH).
    Huestis MA; Henningfield JE; Cone EJ
    J Anal Toxicol; 1992; 16(5):283-90. PubMed ID: 1338216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.
    Johansson E; Halldin MM
    J Anal Toxicol; 1989; 13(4):218-23. PubMed ID: 2550702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans.
    Thieme U; Schelling G; Hauer D; Greif R; Dame T; Laubender RP; Bernhard W; Thieme D; Campolongo P; Theiler L
    Drug Test Anal; 2014; 6(1-2):17-23. PubMed ID: 24424856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach.
    Awasthi R; An G; Donovan MD; Boles Ponto LL
    J Pharm Sci; 2018 Feb; 107(2):745-755. PubMed ID: 28942005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise increases plasma THC concentrations in regular cannabis users.
    Wong A; Montebello ME; Norberg MM; Rooney K; Lintzeris N; Bruno R; Booth J; Arnold JC; McGregor IS
    Drug Alcohol Depend; 2013 Dec; 133(2):763-7. PubMed ID: 24018317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marijuana effect and delta-9-tetrahydrocannabinol plasma level.
    Chiang CW; Barnett G
    Clin Pharmacol Ther; 1984 Aug; 36(2):234-8. PubMed ID: 6086207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man.
    Wall ME; Perez-Reyes M
    J Clin Pharmacol; 1981; 21(S1):178S-189S. PubMed ID: 6271823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.